Non-invasive bioelectrical therapy suppresses retinal neovascularization by modulating cellular metabolism and inflammation
These findings establish TpES as a dual-action therapy that mitigates both inflammation and pathological angiogenesis by modulating microglial and endothelial metabolism. Given its noninvasive nature and ability to target key pathways in retinal pathology, TpES represents a promising therapeutic strategy for AMD, DR, and other retinal vascular diseases.
Authors
- Menglu Yang
- Ajay Ashok (ORCID: https://orcid.org/0000-0003-4354-1467)
- Karen Chang (ORCID: https://orcid.org/0000-0002-5920-6201)
- Darlene A. Dartt (ORCID: https://orcid.org/0000-0002-0576-6932)
- Christina Yen (ORCID: https://orcid.org/0000-0002-6145-4693)
- Daisy Y. Shu (ORCID: https://orcid.org/0000-0002-5382-6450)
- Anton Lennikov (ORCID: https://orcid.org/0000-0001-8625-1211)
- Aruvi Vijikumar (ORCID: https://orcid.org/0000-0003-1830-3029)
- Zhengping Hu (ORCID: https://orcid.org/0000-0001-7369-1314)
- Kin‐Sang Cho (ORCID: https://orcid.org/0000-0003-4285-615X)
- Farris Elzaridi
- Lu Huang (ORCID: https://orcid.org/0009-0006-9649-3971)
- Julie Chen
- Dong Feng Chen (ORCID: https://orcid.org/0000-0001-6283-8843)
- William P. Miller
- Magali Saint Geniez
- Matthijs Tsonas
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- Leiden University Medical Center (NL)
- Smith-Kettlewell Eye Research Institute (US)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1186/s12964-025-02451-1
- Primary Topic
- Planarian Biology and Electrostimulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Harvard NeuroDiscovery Center
- BrightFocus Foundation
- Massachusetts Lions Eye Research Fund
- National Institutes of Health
- National Eye Institute